New insider Mukadam Sophie claimed ownership of 6,016 shares (SEC Form 3)
$BNTC
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 01/01/2025 |
3. Issuer Name and Ticker or Trading Symbol
Benitec Biopharma Inc. [ BNTC ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock, par value $0.0001 per share | 6,016 | I | By spouse |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Options (right to buy) | (1) | 12/08/2030 | Common Stock | 141 | $50.66 | D | |
| Options (right to buy) | (2) | 06/13/2031 | Common Stock | 1,034 | $79.9 | D | |
| Options (right to buy) | (3) | 06/12/2033 | Common Stock | 5,294 | $3.91 | D | |
| Options (right to buy) | (4) | 03/05/2034 | Common Stock | 100,000 | $5.21 | D | |
| Options (right to buy) | (5) | 12/27/2034 | Common Stock | 300,000 | $12 | D | |
| Explanation of Responses: |
| 1. The stock options vested in three substantially equal installments on December 9, 2021, December 9, 2022 and December 9, 2023. |
| 2. The stock options vested in three substantially equal installments on June 14, 2022, June 14, 2023, and June 14, 2024. |
| 3. Stock options for 1,764 shares vested on June 13, 2024. The remainder of the stock options will vest in two substantially equal installments on June 13, 2025 and June 13, 2026. |
| 4. The stock options will vest in three substantially equal installments on March 6, 2025, March 6, 2026, and March 6, 2027. |
| 5. The stock options will vest in sixteen substantially equal quarterly installments commencing on March 31, 2025. |
| Remarks: |
| Exhibit 24 - Power of Attorney |
| /s/ Louis Rambo, Attorney-in-Fact for Sophie Mukadam | 01/03/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||